Classification of measles breakthrough cases in an elimination setting using a comprehensive algorithm of laboratory results: why sensitive and specific IgM assays are important.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 20 08 2021
revised: 31 08 2021
accepted: 03 09 2021
pubmed: 12 9 2021
medline: 15 12 2021
entrez: 11 9 2021
Statut: ppublish

Résumé

In 2006, a measles outbreak occurred in Catalonia (Spain), six years after endemic measles was declared eliminated. This study aimed to classify 19 confirmed measles breakthrough cases (BC) using a high-performance avidity assay developed in 2010. Serum specimens were tested by indirect IgG, indirect IgM, capture IgM enzyme immunoassay, an endpoint-titer IgG avidity assay, and a plaque reduction neutralization assay. Serology and RNA detection results were combined in an algorithm for measles confirmation and classification of breakthrough cases and analyzed with clinical and epidemiological data. Of 19 samples, thirteen (68%) were conclusive with the classification of BCs, and six (32%) had false-positive IgM results on an indirect-format assay; they were classified as rash and fever illness of undetermined etiology. BCs were primary vaccine failures (seven or 54%), secondary vaccine failures (four or 31%), and two (15%) could not be classified. In measles elimination settings, high-performing assays and a comprehensive algorithm of laboratory results (IgG, IgM, and RNA detection), including IgG avidity and PRN results when necessary, can assist in accurate laboratory confirmation and classification of suspected measles cases for surveillance. Highly specific IgM assays are required to minimize the number of false-positive results.

Identifiants

pubmed: 34508861
pii: S1201-9712(21)00711-6
doi: 10.1016/j.ijid.2021.09.004
pii:
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin M 0
Measles Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

21-24

Informations de copyright

Published by Elsevier Ltd.

Auteurs

S Mercader (S)

Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. Electronic address: sjm7@cdc.gov.

A Dominguez (A)

Department of Medicine, University of Barcelona, Barcelona, Spain and CIBERESP, Institut of Health Carlos III, Madrid, Spain.

N Torner (N)

Department of Medicine, University of Barcelona, Barcelona, Spain and CIBERESP, Institut of Health Carlos III, Madrid, Spain; Public Health Agency of Catalonia, Barcelona, Spain.

J Costa (J)

Virology Unit, Centre de Diagnòstic Biomèdic, Hospital Clínic, Barcelona, Spain.

S B Sowers (SB)

Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

A Martinez (A)

Public Health Agency of Catalonia, Barcelona, Spain.

W J Bellini (WJ)

Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA; Retired.

C J Hickman (CJ)

Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH